{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:44:06Z","timestamp":1780321446341,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"am","delay-in-days":704,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000057","name":"NIGMS","doi-asserted-by":"publisher","award":["R44GM122196-02A1"],"award-info":[{"award-number":["R44GM122196-02A1"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"NIEHS","doi-asserted-by":"publisher","award":["R43ES031038"],"award-info":[{"award-number":["R43ES031038"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bmc.2022.117043","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T02:19:34Z","timestamp":1664849974000},"page":"117043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Multiple approaches to repurposing drugs for neuroblastoma"],"prefix":"10.1016","volume":"73","author":[{"given":"Laura","family":"Rank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana C.","family":"Puhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy M.","family":"Havener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Foil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley M.","family":"Zorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Monakhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Riabova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Makarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Ekins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2022.117043_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fnmol.2019.00009","article-title":"Neuroblastoma-A Neural Crest Derived Embryonal Malignancy","volume":"12","author":"Johnsen","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.bmc.2022.117043_b0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2020.05.010","article-title":"Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma","volume":"136","author":"Moreno","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2022.117043_b0015","doi-asserted-by":"crossref","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmc.2022.117043_b0020","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/000992287000900409","article-title":"Congenital neuroblastoma. Symptoms in the mother during pregnancy","volume":"9","author":"Voute","year":"1970","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.bmc.2022.117043_b0025","first-page":"755","article-title":"Epidemiology and etiology of neuroblastoma: an overview","volume":"23","author":"Izbicki","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bmc.2022.117043_b0030","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/1817-1745.199462","article-title":"Neuroblastoma presenting as opsoclonus-myoclonus: A series of six cases and review of literature","volume":"11","author":"Meena","year":"2016","journal-title":"J Pediatr Neurosci"},{"key":"10.1016\/j.bmc.2022.117043_b0035","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/bjc.1990.383","article-title":"Trends in survival for childhood cancer in Britain diagnosed 1971\u201385","volume":"62","author":"Stiller","year":"1990","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2022.117043_b0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41467-019-13817-8","article-title":"Integrative discovery of treatments for high-risk neuroblastoma","volume":"11","author":"Almstedt","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2022.117043_b0045","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.2147\/DDDT.S147384","article-title":"Entrectinib and other ALK\/TRK inhibitors for the treatment of neuroblastoma","volume":"12","author":"Pacenta","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmc.2022.117043_b0050","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cbpa.2021.06.001","article-title":"Recent advances in drug repurposing using machine learning","volume":"65","author":"Urbina","year":"2021","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.bmc.2022.117043_b0055","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acs.chemrestox.0c00466","article-title":"The Antiviral Drug Tilorone Is a Potent and Selective Inhibitor of Acetylcholinesterase","volume":"34","author":"Vignaux","year":"2021","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.bmc.2022.117043_b0060","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1158\/1535-7163.MCT-17-0841","article-title":"A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy","volume":"17","author":"Sidarovich","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2022.117043_b0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41389-019-0186-3","article-title":"Repurposing a psychoactive drug for children with cancer: p27(Kip1)-dependent inhibition of metastatic neuroblastomas by Prozac","volume":"9","author":"Bibbo","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.bmc.2022.117043_b0070","article-title":"Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma","author":"Swift","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.bmc.2022.117043_b0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2020.01.015","article-title":"Preclinical models for neuroblastoma: Advances and challenges","volume":"474","author":"Nolan","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.bmc.2022.117043_b0080","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41416-019-0682-4","article-title":"Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy","volume":"122","author":"Kamili","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2022.117043_b0085","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1038\/s41467-020-18987-4","article-title":"Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations","volume":"11","author":"Brady","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2022.117043_b0090","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s10147-012-0417-5","article-title":"Development of treatment strategies for advanced neuroblastoma","volume":"17","author":"Hara","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.bmc.2022.117043_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10040113","article-title":"ALK in Neuroblastoma: Biological and Therapeutic Implications","volume":"10","author":"Trigg","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2022.117043_b0100","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/apm.12940","article-title":"Targeting anaplastic lymphoma kinase in neuroblastoma","volume":"127","author":"Umapathy","year":"2019","journal-title":"APMIS"},{"key":"10.1016\/j.bmc.2022.117043_b0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-1-0716-1437-2_2","article-title":"Considerations for the Use of SH-SY5Y Neuroblastoma Cells in Neurobiology","volume":"2311","author":"Kovalevich","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bmc.2022.117043_b0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-213X-9-12","article-title":"Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells","volume":"9","author":"Acosta","year":"2009","journal-title":"BMC Dev Biol"},{"key":"10.1016\/j.bmc.2022.117043_b0115","doi-asserted-by":"crossref","unstructured":"Twarog NR, Stewart E, Hammill CV, A AS. BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action, Sci Rep 2016; 6: 25523.","DOI":"10.1038\/srep25523"},{"key":"10.1016\/j.bmc.2022.117043_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104908","article-title":"Repurposing Pyramax\u00ae for the Treatment of Ebola Virus Disease: Additivity of the Lysosomotropic Pyronaridine and Non-Lysosomotropic Artesunate","volume":"182","author":"Lane","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmc.2022.117043_b0125","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1158\/0008-5472.CAN-10-2956","article-title":"The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers","volume":"70","author":"Sasaki","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2022.117043_b0130","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2022.117043_b0135","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study","volume":"14","author":"Moss\u00e9","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bmc.2022.117043_b0140","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.17137","article-title":"Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models","volume":"6","author":"Wang","year":"2017","journal-title":"Elife"},{"key":"10.1016\/j.bmc.2022.117043_b0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.bbrc.2009.09.044","article-title":"Positive auto-regulation of MYCN in human neuroblastoma","volume":"390","author":"Suenaga","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2022.117043_b0150","doi-asserted-by":"crossref","first-page":"e0257718","DOI":"10.1371\/journal.pone.0257718","article-title":"Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides","volume":"16","author":"Ota","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2022.117043_b0155","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1093\/nar\/gkl619","article-title":"Expression of C-terminal deleted p53 isoforms in neuroblastoma","volume":"34","author":"Goldschneider","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2022.117043_b0160","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.bbrc.2007.01.057","article-title":"Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line","volume":"354","author":"Nakamura","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2022.117043_b0165","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41429-020-0351-0","article-title":"Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii","volume":"73","author":"Chiba","year":"2020","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.bmc.2022.117043_b0170","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/pbc.24564","article-title":"FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway","volume":"60","author":"Li","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bmc.2022.117043_b0175","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/1535-7163.MCT-17-0379","article-title":"Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance","volume":"16","author":"Lifshitz","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2022.117043_b0180","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00535-013-0848-4","article-title":"BAY 11\u20137082, a nuclear factor-\u03baB inhibitor, induces apoptosis and S phase arrest in gastric cancer cells","volume":"49","author":"Chen","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.bmc.2022.117043_b0185","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1111\/febs.12283","article-title":"The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases","volume":"280","author":"Krishnan","year":"2013","journal-title":"FEBS J"},{"key":"10.1016\/j.bmc.2022.117043_b0190","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/416036","article-title":"BAY 11\u20137082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets","volume":"2012","author":"Lee","year":"2012","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.bmc.2022.117043_b0195","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer","volume":"18","author":"Singh","year":"2019","journal-title":"Ann Afr Med"},{"key":"10.1016\/j.bmc.2022.117043_b0200","doi-asserted-by":"crossref","first-page":"e59292","DOI":"10.1371\/journal.pone.0059292","article-title":"The IKK inhibitor Bay 11\u20137082 induces cell death independent from inhibition of activation of NF\u03baB transcription factors","volume":"8","author":"Rauert-Wunderlich","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2022.117043_b0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gene.2019.04.039","article-title":"NF-\u03baB inhibitor, BAY11-7082, suppresses M2 tumor-associated macrophage induced EMT potential via miR-30a\/NF-\u03baB\/Snail signaling in bladder cancer cells","volume":"710","author":"Zhang","year":"2019","journal-title":"Gene"},{"key":"10.1016\/j.bmc.2022.117043_b0210","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.7150\/jca.34285","article-title":"Synergistic inhibition of lung cancer cells by EGCG and NF-\u03baB inhibitor BAY11-7082","volume":"10","author":"Zhang","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.bmc.2022.117043_b0215","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/bjc.2012.485","article-title":"Bay11-7082 inhibits the disintegration of the lymphendothelial barrier triggered by MCF-7 breast cancer spheroids; the role of ICAM-1 and adhesion","volume":"108","author":"Viola","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bmc.2022.117043_b0220","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3892\/ol.2021.12562","article-title":"Nuclear factor-\u03baB inhibitor Bay11-7082 inhibits gastric cancer cell proliferation by inhibiting Gli1 expression","volume":"21","author":"Yan","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.bmc.2022.117043_b0225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: Beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell Signal"},{"key":"10.1016\/j.bmc.2022.117043_b0230","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/acsinfecdis.0c00052","article-title":"Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential","volume":"6","author":"Xu","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmc.2022.117043_b0235","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1158\/1078-0432.CCR-18-4117","article-title":"Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma","volume":"25","author":"Huang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2022.117043_b0240","doi-asserted-by":"crossref","first-page":"7454","DOI":"10.1021\/acsomega.0c05996","article-title":"Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine. In Vitro Activity against SARS-CoV-2 and Potential Mechanisms","volume":"6","author":"Puhl","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2022.117043_b0245","doi-asserted-by":"crossref","first-page":"e0007890","DOI":"10.1371\/journal.pntd.0007890","article-title":"Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection","volume":"13","author":"Lane","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.bmc.2022.117043_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104863","article-title":"Pyronaridine tetraphosphate efficacy against Ebola virus infection in guinea pig","volume":"181","author":"Lane","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmc.2022.117043_b0255","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1475-2875-11-270","article-title":"Review of pyronaridine anti-malarial properties and product characteristics","volume":"11","author":"Croft","year":"2012","journal-title":"Malar J"},{"key":"10.1016\/j.bmc.2022.117043_b0260","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acsinfecdis.2c00091","article-title":"Pyronaridine Protects against SARS-CoV-2 Infection in Mouse","volume":"8","author":"Puhl","year":"2022","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.bmc.2022.117043_b0265","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.12688\/f1000research.7217.1","article-title":"Machine learning models identify molecules active against the Ebola virus in vitro","volume":"4","author":"Ekins","year":"2015","journal-title":"F1000Res"},{"key":"10.1016\/j.bmc.2022.117043_b0270","doi-asserted-by":"crossref","first-page":"e0206467","DOI":"10.1371\/journal.pone.0206467","article-title":"Pyronaridine exerts potent cytotoxicity on human breast and hematological cancer cells through induction of apoptosis","volume":"13","author":"Villanueva","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2022.117043_b0275","unstructured":"NCI, NCI-60 Human Tumor Cell Lines Screen, 2020."},{"key":"10.1016\/j.bmc.2022.117043_b0280","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0378-4347(96)00410-0","article-title":"Determination of pyronaridine in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies","volume":"690","author":"Jayaraman","year":"1997","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.bmc.2022.117043_b0285","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13060837","article-title":"Cathepsin D-Managing the Delicate Balance","volume":"13","author":"Mijanovic","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bmc.2022.117043_b0290","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/jnc.13412","article-title":"Mitochondrial and lysosomal biogenesis are activated following PINK1\/parkin-mediated mitophagy","volume":"136","author":"Ivankovic","year":"2016","journal-title":"J Neurochem"},{"key":"10.1016\/j.bmc.2022.117043_b0295","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3389\/fonc.2020.01156","article-title":"Targeting Lysosomes in Cancer as Promising Strategy to Overcome Chemoresistance-A Mini Review","volume":"10","author":"Geisslinger","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmc.2022.117043_b0300","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1242\/jcs.091181","article-title":"Lysosomal cell death at a glance","volume":"126","author":"Aits","year":"2013","journal-title":"J Cell Sci"},{"key":"10.1016\/j.bmc.2022.117043_b0305","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/1078-0432.CCR-15-0379","article-title":"Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma","volume":"22","author":"Krytska","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmc.2022.117043_b0310","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.tranon.2017.04.008","article-title":"Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK","volume":"10","author":"Zhang","year":"2017","journal-title":"Transl Oncol"},{"key":"10.1016\/j.bmc.2022.117043_b0315","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1016\/S0959-8049(98)00228-7","article-title":"Etoposide: four decades of development of a topoisomerase II inhibitor","volume":"34","author":"Hande","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmc.2022.117043_b0320","doi-asserted-by":"crossref","first-page":"e23398","DOI":"10.1002\/bip.23398","article-title":"Pyronaridine: An update of its pharmacological activities and mechanisms of action","volume":"112","author":"Bailly","year":"2021","journal-title":"Biopolymers"},{"key":"10.1016\/j.bmc.2022.117043_b0325","doi-asserted-by":"crossref","first-page":"12982","DOI":"10.1038\/s41598-020-70026-w","article-title":"Synergistic drug combinations and machine learning for drug repurposing in chordoma","volume":"10","author":"Anderson","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2022.117043_b0330","doi-asserted-by":"crossref","unstructured":"Puhl AC, Gomes GF, Damasceno S. et al., Pyronaridine Protects Against SARS-CoV-2 in Mouse, bioRxiv, 2021. 2021.2009.2030.462449.","DOI":"10.1101\/2021.09.30.462449"},{"key":"10.1016\/j.bmc.2022.117043_b0335","doi-asserted-by":"crossref","unstructured":"Gaulton A, Hersey A, Nowotka M. et al. The ChEMBL database in 2017, Nucleic Acids Res 2017; 45: D945-D954.","DOI":"10.1093\/nar\/gkw1074"},{"key":"10.1016\/j.bmc.2022.117043_b0340","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/acs.molpharmaceut.0c01013","article-title":"Bioactivity Comparison across Multiple Machine Learning Algorithms Using over 5000 Datasets for Drug Discovery","volume":"18","author":"Lane","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.bmc.2022.117043_b0345","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1021\/acs.molpharmaceut.8b00546","article-title":"Comparing Multiple Machine Learning Algorithms and Metrics for Estrogen Receptor Binding Prediction","volume":"15","author":"Russo","year":"2018","journal-title":"Mol Pharm"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622004369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622004369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:30:01Z","timestamp":1778574601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089622004369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":69,"alternative-id":["S0968089622004369"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2022.117043","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple approaches to repurposing drugs for neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2022.117043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117043"}}